Galectin Therapeutics Inc. (NasdaqCM: GALT)
Health Care · Biotechnology · US
$3.95
+0.25% today · -16.5% 1Y
Galectin Therapeutics Inc. (NasdaqCM: GALT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $397.35M and employs 9 people.
Over the last twelve months the share price has lost 16.5%, trading between 2.03 and 7.13.
Tweenvest scores Galectin Therapeutics Inc. across four factors: quality 22/100, value 89/100. Its strongest factor is value.
GALT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $397.35M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.43
- Dividend yield
- —
- Beta (5Y)
- 0.38
- 52-week high
- $7.13
- 52-week low
- $2.03
- Avg volume (3M)
- —
- Shares outstanding
- 100.85M
- Employees
- 9
- Next earnings
- —
About Galectin Therapeutics Inc.
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
- ISIN
- US3632252025
- Founded
- 2000
- Listed since
- Sep 4, 2002
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AP Biosciences, Inc.TPEX: 6945 | $405.68M | NT$133.00 | -2.21% |
| Eikon Therapeutics, Inc.NasdaqGS: EIKN | $404.61M | $7.40 | -0.94% |
| Prelude Therapeutics IncorporatedNasdaqGS: PRLD | $400.65M | $3.89 | +5.99% |
| Laekna, Inc.SEHK: 2105 | $400.21M | HK$7.37 | -15.77% |
| Kyverna Therapeutics, Inc.NasdaqGS: KYTX | $395.18M | $6.44 | +0.70% |
| Arcturus Therapeutics Holdings Inc.NasdaqGM: ARCT | $390.53M | $13.67 | -0.51% |
| C4 Therapeutics, Inc.NasdaqGS: CCCC | $388.76M | $3.16 | 0.00% |
| vTv Therapeutics Inc.NasdaqCM: VTVT | $387.40M | $31.18 | +2.00% |
Figures last refreshed Oct 11, 2026.